The aim of our present study was to investigate in patients of the LIFE-Heart study [8,9,10,11] the associations of five promising, standardized, and robust cardiovascular and inflammatory biomarkers (copeptin, hsTNT, NT-proBNP, hsCRP, and interleukin-6) for non-invasive identification of CAD patients, and mortality risk stratification to enable more precisely primary and secondary cardiovascular prevention. This evidence concerns the gene AVP and coronary artery disorder.